GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » Gross-Profit-to-Asset %

OraSure Technologies (OraSure Technologies) Gross-Profit-to-Asset %

: 29.85% (As of Dec. 2023)
View and export this data going back to 1992. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. OraSure Technologies's annualized Gross Profit for the quarter that ended in Dec. 2023 was $140.5 Mil. OraSure Technologies's average Total Assets over the quarter that ended in Dec. 2023 was $470.6 Mil. Therefore, OraSure Technologies's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 29.85%.


OraSure Technologies Gross-Profit-to-Asset % Historical Data

The historical data trend for OraSure Technologies's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OraSure Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.45 25.35 25.69 32.80 37.03

OraSure Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.48 58.27 23.11 38.89 29.85

Competitive Comparison

For the Medical Instruments & Supplies subindustry, OraSure Technologies's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OraSure Technologies Gross-Profit-to-Asset % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, OraSure Technologies's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where OraSure Technologies's Gross-Profit-to-Asset % falls into.



OraSure Technologies Gross-Profit-to-Asset % Calculation

OraSure Technologies's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=171.652/( (444.18+482.845)/ 2 )
=171.652/463.5125
=37.03 %

OraSure Technologies's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=140.504/( (458.432+482.845)/ 2 )
=140.504/470.6385
=29.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


OraSure Technologies Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


OraSure Technologies (OraSure Technologies) Business Description

Traded in Other Exchanges
Address
220 East First Street, Bethlehem, PA, USA, 18015
OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.
Executives
Kathleen Gallagher Weber officer: Chief Product Officer 220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller officer: VP, Finance and Controller 220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath officer: Chief Financial Officer C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster director ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano director 33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano director 220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton director, officer: President & CEO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason officer: Interim CFO/SVP IR 1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs director C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin director 21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora director 64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer officer: President of Diagnostics 1 CRESENT PLACE, SHORT HILLS NJ 07078